Abstract Library

#2793 A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)

Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Weber M

Authors: Fottner C, Apostolidis L, Ferrata M, Krug S, Michl P,

Keywords: NEC, NEN G3, check-point inhibitor, Avelumab, anti-PD-L1-antibody, immunotherapy,

#2068 Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)

Introduction: Immuno check-point inhibitors development in grade 1-2 NENs is limited by low mutation tumor load and PD-1/PDL-1 expression. The combination of an PDL-1 and CTLA-4 inhibitors could increase the probability of success in this setting. In high grade NENs the rational for immunotherapy is stronger based on experiences in small cell lung cancer.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Hernando-Cubero J

Authors: Hernando-Cubero J, Manzano J, Benavent M, Lopez C, Teulé R,

Keywords: Durvalumab, Tremelimumab, Neuroendocrine, Immunotherapy,